{'fraction_non_alphanumeric': 0.047337278106508875, 'fraction_numerical': 0.047337278106508875, 'mean_word_length': 4.549180327868853, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Recent progress in the treatment of adult acute leukemia].

Due to the advance of chemotherapy and bone marrow transplantation, adult acute leukemia has become a curable disease. In acute myeloid leukemia, the JALSG AML89 study resulted in 77% complete remission (CR) rate in 326 adults and 38% 4.5-year disease-free survival (DFS) in CR cases. However, the result of acute lymphoblastic leukemia in the JALSG ALL87 study is not satisfactory; 84% CR in 116 adults and only 24% 6-year DFS. For acute promyelocytic leukemia (APL), all-trans retinoic acid works remarkably, and the JALSG AML92 study for newly diagnosed APL resulted in 89% CR in 109 adults and 81% 2.5-year DFS.